Radium-223 chloride: Radiation safety, tolerability, and survival gain in patients with castration-resistant prostate cancer (CRPC) and bone metastases

被引：0
|
作者：
Lewington, Valerie [1 ]
Lamey, Roy [2 ]
Staudacher, Karin [3 ]
Vogelzang, Nicholas [2 ]
机构：
[1] Guys & St Thomas Hosp, London, England
[2] Comprehens Canc Ctr Nevada, US Oncol Res, Las Vegas, NV USA
[3] Algeta ASA, Oslo, Norway
来源：
JOURNAL OF NUCLEAR MEDICINE | 2012年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
222
引用
收藏
页数：1
相关论文
共 50 条
  • [41] External Beam Radiation Therapy (EBRT) Use and Safety With Radium-223 Dichloride (Ra-223) in Patients With Castration-Resistant Prostate Cancer (CRPC) and Symptomatic Bone Metastases (mets) From the ALSYMPCA Trial
    Finkelstein, S. E.
    Michalski, J. M.
    O'Sullivan, J.
    Parker, C.
    Garcia-Vargas, J.
    Sartor, O.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S201 - S201
  • [42] Clinical experience of using the radium-223 in patients with bone metastasis of castration-resistant prostate cancer
    Yurmazov, Z. A.
    Usynin, E. A.
    Medvedeva, A. A.
    Polyakov, A. A.
    Lushnikova, N. A.
    Chernov, V., I
    Spirina, L., V
    ONKOUROLOGIYA, 2022, 18 (01): : 70 - 76
  • [43] Phase II clinical study of radium-223 chloride (BAY 88-8223) in Japanese patients with symptomatic castration-resistant prostate cancer (CRPC) with bone metastases.
    Uemura, Hiroji
    Nagamori, Satoshi
    Wakumoto, Yoshiaki
    Uemura, Hirotsugu
    Kimura, Go
    Yokomizo, Akira
    Kikukawa, Hiroaki
    Mizokami, Atsushi
    Kosaka, Takeo
    Masumori, Naoya
    Kawasaki, Yoshihide
    Yonese, Junji
    Nasu, Yasutomo
    Fukasawa, Satoshi
    Sugiyama, Takayuki
    Uemura, Motohide
    Yamaguchi, Iku
    Tsutsui, Hirokazu
    Matsunaga, Eisuke
    Matsubara, Nobuaki
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [44] Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).
    Parker, Chris
    Nilsson, Sten
    Heinrich, Daniel
    O'Sullivan, Joe M.
    Fossa, Sophie D.
    Chodacki, Ales
    Wiechno, Pawel J.
    Logue, John P.
    Seke, Mihalj
    Widmark, Anders
    Johannessen, Dag Clement
    Hoskin, Peter
    Bottomley, David
    Coleman, Robert Edward
    Vogelzang, Nicholas J.
    O'Bryan-Tear, C. Gillies
    Garcia-Vargas, Jose E.
    Shan, Minghua
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [45] ESTIMATING THE ECONOMIC IMPACT OF RADIUM RA 223 DICHLORIDE (RADIUM-223) IN TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH SYMPTOMATIC BONE METASTASES AND NO KNOWN VISCERAL METASTATIC DISEASE
    Valderrama, A.
    Bilir, S. P.
    Wehler, E. A.
    Seal, B. S.
    Wen, L.
    Yaldo, A.
    Munakata, J.
    VALUE IN HEALTH, 2014, 17 (03) : A74 - A74
  • [46] RADIUM-223 CHLORIDE, A NOVEL, HIGHLY TARGETED ALPHA-PHARMACEUTICAL FOR TREATMENT OF BONE METASTASES FROM CASTRATION-RESISTANT PROSTATE CANCER (CRPC): HEMATOLOGIC AND SAFETY PROFILE WITH REPEATED DOSING
    Parker, C.
    Aksnes, A.
    Haugen, I.
    Bolstad, B.
    Nilsson, S.
    ANNALS OF ONCOLOGY, 2010, 21 : 277 - 278
  • [47] Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
    Axel Heidenreich
    Silke Gillessen
    Daniel Heinrich
    Daniel Keizman
    Joe M. O’Sullivan
    Joan Carles
    Manfred Wirth
    Kurt Miller
    John Reeves
    Monica Seger
    Sten Nilsson
    Fred Saad
    BMC Cancer, 19
  • [48] Radium-223 dichloride (Ra-223) efficacy and safety in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Phase 3 ALSYMPCA study findings stratified by age group
    Wiechno, P.
    Helle, S. I.
    Logue, J.
    Nilsson, S.
    Sartor, O.
    Coleman, R. E.
    Kliment, J.
    Fang, F.
    Parker, C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S690 - S691
  • [49] Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
    Heidenreich, Axel
    Gillessen, Silke
    Heinrich, Daniel
    Keizman, Daniel
    O'Sullivan, Joe M.
    Carles, Joan
    Wirth, Manfred
    Miller, Kurt
    Reeves, John
    Seger, Monica
    Nilsson, Sten
    Saad, Fred
    BMC CANCER, 2019, 19 (1)
  • [50] Radiographic and laboratory assessment of bone metastases in castration-resistant prostate cancer patients undergoing Radium-223 dichloride therapy
    Takalkar, Amol
    Paryani, Bhavna
    Skweres, Justin
    Adams, Scott
    Devarakonda, Srinivas
    Dhawan, Manish
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
12345